Genes & Genomics

, Volume 40, Issue 4, pp 423–428 | Cite as

BMP3 promoter hypermethylation in plasma-derived cell-free DNA in colorectal cancer patients

  • Parisa Rokni
  • Afsaneh Mojtabanezhad Shariatpanahi
  • Ebrahim Sakhinia
  • Mohammad Amin Kerachian
Research Article


Detecting cfDNA in plasma or serum could serve as a ‘liquid biopsy’, for circulating tumor DNA with aberrant methylation patterns offer a possible method for early detection of several cancers which could avoid the need for tumor tissue biopsies. Bone Morphogenetic Protein 3 (BMP3) was identified as a candidate tumor suppressor gene putatively down-regulated in colorectal cancer (CRC). In this study, we aimed to assess the potential role of BMP3 promoter methylation changes in plasma DNA for detection of colorectal cancerous and precancerous lesions. Plasma DNA samples were extracted from 50 patients with histologically diagnosed polyps or tumor and 50 patients reported negative for polyps or tumors. The procedure consists of bisulfite conversion of the extracted DNA, purification of bis-DNA, and BMP3 methylation status analysis by using the bisulfite specific high resolution melting analysis. This study demonstrated that there was a significantly higher frequency of BMP3 methylated DNA in plasma in patients with polyps versus healthy controls with a sensitivity and specificity of 40 and 94%, respectively. In conclusion, our results demonstrated that BMP3 DNA methylation in plasma had not have sufficient sensitivity and it should be used in combination with other biomarkers for the detection of CRC.


Biomarker Colorectal Cancer Methylation 



This study was supported financially by Tabriz University of Medical Sciences, and Reza Radiotherapy and Oncology Center, Mashhad, Iran. Our sincere thanks also go to Mr. Ebrahim Pouladin and Mrs. Nafiseh Shalchi for their close support in CRC research programs. We would also give special thanks to Dr. Abdorasoul Hayatbakhsh, Miss. Maryam Yassi and Adeleh Rezaie, Mrs. Neda Ziafati, and Zohreh Alizadeh for their cooperation in this study.


This study was supported financially by Tabriz University of Medical Sciences (Grant # 54125388), and Reza Radiotherapy and Oncology Center, Mashhad, Iran.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consents were obtained from all individual participants included in this study.


  1. Ahlquist DA, Taylor WR, Mahoney DW, Zou H, Domanico M, Thibodeau SN, Boardman LA, Berger BM, Lidgard GP (2012a) The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 10:272–277.e271CrossRefPubMedGoogle Scholar
  2. Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat LF et al (2012b) Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142:248–226CrossRefPubMedGoogle Scholar
  3. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F (2017) Global patterns and trends in colorectal cancer incidence and mortality. Gut 66:683–691CrossRefPubMedGoogle Scholar
  4. Ashktorab H, Daremipouran M, Goel A, Varma S, Leavitt R, Sun X, Brim H (2014) DNA methylome profiling identifies novel methylated genes in African American patients with colorectal neoplasia. Epigenetics 9:503–512CrossRefPubMedPubMedCentralGoogle Scholar
  5. Behrouz Sharif S, Hashemzadeh S, Mousavi Ardehaie R, Eftekharsadat A, Ghojazadeh M, Mehrtash AH, Estiar MA, Teimoori-Toolabi L, Sakhinia E (2016) Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker. Oncol Lett 12:5335–5343CrossRefPubMedPubMedCentralGoogle Scholar
  6. Berger BM, Levin B, Hilsden RJ (2016) Multitarget stool DNA for colorectal cancer screening: a review and commentary on the United States preventive services draft guidelines. World J Gastrointest Oncol 8:450–458CrossRefPubMedPubMedCentralGoogle Scholar
  7. Danese E, Minicozzi AM, Benati M, Montagnana M, Paviati E, Salvagno GL, Lima-Oliveira G, Gusella M, Pasini F, Lippi G et al (2015) Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. PLoS ONE 10:e0126417CrossRefPubMedPubMedCentralGoogle Scholar
  8. Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579–586CrossRefPubMedPubMedCentralGoogle Scholar
  9. Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV (2013) The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 14:18925–18958CrossRefPubMedPubMedCentralGoogle Scholar
  10. Galanopoulos M, Tsoukalas N, Papanikolaou IS, Tolia M, Gazouli M, Mantzaris GJ (2017) Abnormal DNA methylation as a cell-free circulating DNA biomarker for colorectal cancer detection: a review of literature. World J Gastrointest Oncol 9:142–152CrossRefPubMedPubMedCentralGoogle Scholar
  11. Gonzalez-Pons M, Cruz-Correa M (2015) Colorectal cancer biomarkers: where are we now?. Biomed Res Int 2015:149014CrossRefPubMedPubMedCentralGoogle Scholar
  12. Grützmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, Miehlke S, Stolz T, Model F, Roblick UJ et al (2008) Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 3:e3759CrossRefPubMedPubMedCentralGoogle Scholar
  13. Haggar FA, Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22:191–197CrossRefPubMedPubMedCentralGoogle Scholar
  14. Hessami Arani S, Kerachian MA (2017) Rising rates of colorectal cancer among younger Iranians: is diet to blame? Curr Oncol 24:e131–e137CrossRefPubMedPubMedCentralGoogle Scholar
  15. Houshmand M, Abbaszadegan MR, Kerachian MA (2017) Assessment of bone morphogenetic protein 3 methylation in Iranian patients with colorectal cancer. Middle East J Dig Dis 9:158–163CrossRefPubMedPubMedCentralGoogle Scholar
  16. Jin P, Kang Q, Wang X, Yang L, Yu Y, Li N, He Y, Han X, Hang J, Zhang J (2015) Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol 30:830–833CrossRefGoogle Scholar
  17. Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN Jr, Lu C, Gershenson DM et al (2006) Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 5:1369–1374CrossRefPubMedGoogle Scholar
  18. Kim HJ, Yu MH, Kim H, Byun J, Lee C (2008) Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep 41:685–692CrossRefPubMedGoogle Scholar
  19. Lamb YN, Dhillon S (2017) Epi proColon® 2.0 CE: a blood-based screening test for colorectal cancer. Mol Diagn Ther 21:225–232CrossRefPubMedGoogle Scholar
  20. Lange CP, Laird PW (2013) Clinical applications of DNA methylation biomarkers in colorectal cancer. Epigenomics 5:105–108CrossRefPubMedGoogle Scholar
  21. Lange CP, Campan M, Hinoue T, Schmitz RF, van der Meulen-de Jong AE, Slingerland H, Kok PJ, van Dijk CM, Weisenberger DJ, Shen H et al (2012) Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS ONE 7:e50266CrossRefPubMedPubMedCentralGoogle Scholar
  22. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR et al. (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the american cancer society, the US multi-society task force on colorectal cancer, and the american college of radiology. CA Cancer J Clin 58:130–160CrossRefPubMedGoogle Scholar
  23. Loh K, Chia JA, Greco S, Cozzi SJ, Buttenshaw RL, Bond CE, Simms LA, Pike T, Young JP, Jass JR et al (2008) Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosomes Cancer 47:449–460CrossRefPubMedGoogle Scholar
  24. Mansour H (2014) Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection. Front Genet 5:182CrossRefPubMedPubMedCentralGoogle Scholar
  25. Okugawa Y, Grady WM, Goel A (2015) Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 149:1204–1225.e1212CrossRefPubMedPubMedCentralGoogle Scholar
  26. Park SK, Baek HL, Yu J, Kim JY, Yang HJ, Jung YS, Choi KY, Kim H, Kim HO, Jeong KU et al (2017) Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest Res 15:495–501CrossRefPubMedPubMedCentralGoogle Scholar
  27. Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437CrossRefPubMedGoogle Scholar
  28. Tanzer M, Balluff B, Distler J, Hale K, Leodolter A, Rocken C, Molnar B, Schmid R, Lofton-Day C, Schuster T et al (2010) Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS ONE 5:e9061CrossRefPubMedPubMedCentralGoogle Scholar
  29. Wojdacz TK, Dobrovic A (2007) Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 35:e41CrossRefPubMedPubMedCentralGoogle Scholar
  30. Zhai RL, Xu F, Zhang P, Zhang WL, Wang H, Wang JL, Cai KL, Long YP, Lu XM, Tao KX et al (2016) The diagnostic performance of stool DNA testing for colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore) 95:e2129CrossRefGoogle Scholar
  31. Zou H, Harrington JJ, Shire AM, Rego RL, Wang L, Campbell ME, Oberg AL, Ahlquist DA (2007) Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomark Prev 16:2686–2696CrossRefGoogle Scholar
  32. Zou H, Allawi H, Cao X, Domanico M, Harrington J, Taylor WR, Yab T, Ahlquist DA, Lidgard G (2012) Quantification of methylated markers with a multiplex methylation-specific technology. Clin Chem 58:375–383CrossRefPubMedGoogle Scholar

Copyright information

© The Genetics Society of Korea and Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  • Parisa Rokni
    • 1
  • Afsaneh Mojtabanezhad Shariatpanahi
    • 2
  • Ebrahim Sakhinia
    • 1
    • 3
  • Mohammad Amin Kerachian
    • 2
    • 4
    • 5
  1. 1.Connective Tissue Research Center, Department of Medical Genetics, Faculty of Medicine and Tabriz Genetic Analysis Centre (TGAC)Tabriz University of Medical SciencesTabrizIran
  2. 2.Cancer Genetics Research UnitReza Radiotherapy and Oncology CenterMashhadIran
  3. 3.Division of Regenerative Medicine, Faculty of Medical and Human Sciences, School of MedicineThe University of ManchesterManchesterUK
  4. 4.Medical Genetics Research CenterMashhad University of Medical SciencesMashhadIran
  5. 5.Department of Medical Genetics, Faculty of MedicineMashhad University of Medical SciencesMashhadIran

Personalised recommendations